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The Bethesda System for Reporting Thyroid Cytopathology 
(BSRTC) was developed in 2008 to facilitate more accurate 
communication of thyroid fine-needle aspiration (FNA) inter-
pretations between clinicians and cytopathologists.1 This sys-
tem, which we adopted in 2010, classifies FNA results into six 
general diagnostic categories, namely, I) nondiagnostic or unsat-
isfactory, II) benign, III) atypia of undetermined significance or 
follicular lesion of undetermined significance, IV) follicular neo-
plasm or suspicious for a follicular neoplasm, V) suspicious for 
malignancy, and VI) malignant.1 Each of these categories is as-
sociated with a risk of malignancy as follows: I) 1-4%, II) 0-3%, 
III) 5-15%, IV) 15-30%, V) 60-75%, and VI) 97-99%.1 Al-
though this system is useful, some studies that have investigat-
ed these risks have had controversial results, especially for cate-
gory III. Furthermore, other studies have reported differences in 
malignancy rates among different institutions and have offered 
various explanations.
In this study, we determined the distribution of FNA results 
and malignancy rates in each diagnostic category of the BSRTC 
in our hospital to determine whether our cytopathologists are 
using this system properly. Specifically, by analyzing data from 
individual cytopathologists, we hoped to ascertain whether our 
hospital has consistent FNA results in each diagnostic category. 
Finally, we suggest ways to improve the accuracy of classifying 
FNA diagnoses.
MATERIALS AND METHODS
Thyroid FNA cytology cases
We retrospectively analyzed 1,538 patients who had thyroid 
nodules that were diagnosed by FNA between October 1, 2011, 
and December 31, 2011, in Gangnam Severance Hospital in 
Korea. This study met criteria for exemption from review from 
the institutional review board. Each FNA diagnosis was made 
independently by one of four cytopathologists. Each thyroid as-
piration sample was analyzed by using liquid-based preparation 
or conventional smear. Some FNAs were originally performed 
by other hospitals; however, in these cases, the slides were re-
Incidence and Malignancy Rates of Diagnoses in the Bethesda System 
for Reporting Thyroid Aspiration Cytology: An Institutional Experience
Ji Hye Park · Sun Och Yoon 
Eun Ju Son1 · Hye Min Kim 
Ji Hae Nahm · SoonWon Hong
Departments of Pathology and 1Radiology, 
Gangnam Severance Hospital, Yonsei University 
College of Medicine, Seoul, Korea
Background: The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) uses six diag-
nostic categories to standardize communication of thyroid fine-needle aspiration (FNA) interpre-
tations between clinicians and cytopathologists. Since several studies have questioned the diag-
nostic accuracy of this system, we examined its accuracy in our hospital. Methods: We calculat-
ed the incidences and malignancy rates of each diagnostic category in the BSRTC for 1,730 
FNAs that were interpreted by four cytopathologists in Gangnam Severance Hospital between 
October 1, 2011, and December 31, 2011. Results: The diagnostic incidences of categories I-VI 
were as follows: 13.3%, 40.6%, 9.1%, 0.4%, 19.3%, and 17.3%, respectively. Similarly, the ma-
lignancy rates of these categories were as follows: 35.3%, 5.6%, 69.0%, 50.0%, 98.7%, and 
98.9%, respectively. In categories II, V, and VI, there were no statistically significant differences in 
the ranges of the malignancy rates among the four cytopathologists. However, there were signifi-
cant differences in the ranges for categories I and III. Conclusions: Our findings suggest that in-
stitutions that use the BSRTC should regularly update their diagnostic criteria. We also propose 
that institutions issue an annual report of incidences and malignancy rates to help other clinicians 
improve the case management of patients with thyroid nodules.
Key Words: Incidence; Biopsy, fine-needle; Thyroid; Pathology; Terminology
Received: February 17, 2014
Revised: March 29, 2014
Accepted: March 31, 2014
Corresponding Author
SoonWon Hong, M.D.
Department of Pathology, Gangnam Severance 
Hospital, Yonsei University College of Medicine,
211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea
Tel: +82-2-2019-3543
Fax: +82-2-3463-2103
E-mail: soonwonh@yuhs.ac
The Korean Journal of Pathology  2014; 48: 133-139
http://dx.doi.org/10.4132/KoreanJPathol.2014.48.2.133
▒ ORIGINAL ARTICLE ▒
http://www.koreanjpathol.org http://dx.doi.org/10.4132/KoreanJPathol.2014.48.2.133
134 • Park JH, et al.
evaluated by our cytopathologists. If a case was diagnosed by 
multiple FNA procedures, then we only considered the last di-
agnosis in the period of 2011. If a patient had more than two 
thyroid nodules, then we considered each FNA diagnosis as a 
separate case.
Follow-up cases
Among 1,538 patients, we included 1,383 patients who had 
follow-up data in the same hospital after diagnosis of their thy-
roid nodules by FNA. The criteria for considering the follow-up 
data were at least one additional FNA, sonography of the thy-
roid or thyroid surgery from the date of initial FNA to Decem-
ber 31, 2013. For follow-up cases that were classified as catego-
ry IV, V, or VI, we only considered the histologic diagnosis of 
surgical cases. However, for follow-up cases that were classified 
as category I, II, or III, we considered both the histologic diag-
nosis of surgical cases (if applicable) and the most recent FNA 
diagnosis during the follow-up period. The most recent FNA 
diagnoses that were classified as category I, II, or III were con-
sidered to be benign.
Statistical analysis
To determine the sensitivity, specificity, false negative rate, 
false positive rate, positive predictive value, and negative pre-
dictive value of the malignancy rate of individual cytopatholo-
gists, we divided the BSRTC categories into two groups: 1) 
surgery is not recommended (categories I, II, and III) because 
the suggested malignancy risks of these categories are low, and 
2) surgery is recommended (categories IV, V, and VI) because 
the suggested malignancy risks of these categories are high. The 
cut-off value for a malignant diagnosis by each cytopathologist 
was calculated by using a receiver operating characteristic 
(ROC) curve. ROC curve analysis was performed with MedCalc 
Statistical Software ver. 12.7.5 (MedCalc Software, Ostend, Bel-
gium). p-values less than .05 were considered to be statistically 
significant.
RESULTS
Patients and distribution of diagnostic categories in all cases
In this study, we examined 1,538 patients who were 14 to 86 
years old (mean, 50 years). The ratio of females to males was 3.8. 
Among these patients, 201 patients had more than two thyroid 
nodules, which resulted in a total of 1,730 FNA cases.
As shown in Table 1, the distribution of all cases in the six 
BSRTC diagnostic categories were as follows: 230 cases (13.3%) 
of category I, 702 cases (40.6%) of category II, 157 cases (9.1%) 
of category III, 7 cases (0.4%) of category IV, 335 cases (19.3%) 
of category V, and 299 cases (17.3%) of category VI. The total 
number and distributions of all cases that were analyzed by each 
cytopathologist is shown in Table 1.
Patients and distribution of outcomes in follow-up cases
The patients who met the criteria for follow-up was 1,383. 
Among these 1,383 patients, 125 had more than two thyroid 
nodules, rendering a total of 1,547 cases which met the follow-
up criteria. Of these 1,547 cases, 213 cases were examined by at 
least one additional FNA, 485 cases were examined by sonogra-
phy and the remaining 849 cases were noted by surgery after 
the initial FNA. The ages of these patients ranged from 14 to 
86 years old (mean, 49 years) and the ratio of females to males 
was 4.0. Their follow-up periods ranged from 2 days to 2 years 
and 2 months (median, 150 days).
The distributions of follow-up diagnoses for each initial 
BSRTC diagnostic classification are shown in Table 2. Specifi-
cally, category I diagnoses (116 cases) remained benign in 75 
cases (64.7%), but were histologically confirmed as papillary 
carcinoma in 41 cases (35.3%). Category II diagnoses (702 cas-
es) remained benign in 663 cases (94.5%), but were histologi-
cally confirmed as papillary carcinoma in 36 cases (5.1%), follic-
ular carcinoma was present in two cases (0.3%), and poorly dif-
ferentiated carcinoma occurred in one case (0.1%). Category III 
diagnoses (126 cases) remained benign in 39 cases (30.9%), but 
were histologically confirmed as papillary carcinoma in 84 cases 
Table 1. Distribution of the diagnostic categories in all cases by each cytopathologist (%)
Diagnostic category of
   Bethesda system
Cytopathologists
Total (n=1,730)
A (n=348) B (n=330) C (n=382) D (n=670)
I 28 (8.0) 50 (15.1) 63 (16.5) 89 (13.3) 230 (13.3)
II 128 (36.8) 151 (45.8) 122 (31.9) 301 (44.9) 702 (40.6)
III 41 (11.8) 18 (5.5) 40 (10.5) 58 (8.7) 157 (9.1)
IV 5 (1.4) 0 (0) 1 (0.3) 1 (0.1) 7 (0.4)
V 57 (16.4) 66 (20.0) 75 (19.6) 137 (20.5) 335 (19.3)
VI 89 (25.6) 45 (13.6) 81 (21.2) 84 (12.5) 299 (17.3)
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(66.7%), follicular carcinoma in two cases (1.6%), and medul-
lary carcinoma in one case (0.8%). Category IV diagnoses (4 cas-
es) were histologically confirmed as follicular carcinoma in two 
cases (50%) and were histologically confirmed as benign in the 
other two cases (50%). Category V diagnoses (314 cases) were 
histologically confirmed as papillary carcinoma in 306 cases 
(97.4%), medullary carcinoma in three cases (1.0%), and poorly 
differentiated thyroid carcinoma in one case (0.3%), but were 
histologically confirmed as benign in three cases (1.1%). Finally, 
category VI diagnoses (285 cases) were histologically confirmed 
as papillary carcinoma in 282 cases (98.9%), but were histologi-
cally confirmed as benign in three cases (1.1%). The histologi-
cally confirmed as benign cases included 53 cases (6.7%) of ade-
nomatous hyperplasia, 13 cases (1.7%) of lymphocytic thyroid-
itis, nine cases (1.1%) of follicular adenoma, one case (0.1%) of a 
hyalinizing trabecular tumor, and three cases (0.4%) of a fibro-
calcific nodule. The total number and distributions of follow-up 
cases that were analyzed by each cytopathologist are shown in 
Table 3. We did not find any significant differences in the ma-
lignancy rates for categories II, V, and VI among four cytopa-
thologists, but found considerable difference in the malignancy 
rates for categories I and III among the cytopathologists. How-
ever, the statistical significance of the differences could not be 
calculated because each FNA diagnosis was made independently 
by one of four cytopathologists. 
Instead, the cut-off value of malignant diagnosis was analyzed 
using ROC curves to see if there is a difference in the malignan-
cy-suggesting category among the cytopathologists, and conse-
quently to see if there is a difference in the diagnoses among the 
cytopathologists. As shown in Fig. 1, we found that all cytopa-
thologists used category III as the cut-off category for differenti-
ating malignant and benign cases (p<.0001).
The sensitivity, specificity, false negative rate, false positive 
rate, positive predictive value, and negative predictive value of 
these malignancy rates for each cytopathologist are shown in 
Table 4.
DISCUSSION
We compared our findings with those reported in 11 previous 
studies2-13 and found several differences, which we attempt to 
explain below. The percentage of FNA diagnoses in the BSRTC 
categories V and VI in our study (19.3% and 17.3%, respec-
tively) was higher than that in other studies (mean, 4.6% and 
7.9%, respectively) (Table 5). In addition, the percentage of 
FNA diagnoses in category II in our study (40.6%) was lower 
than that in previous studies (mean, 62.7%) (Table 5). One pos-
sible reason for these differences may be that our hospital is a re-
ferral hospital for thyroid surgery, so many patients who are sus-
pected of having thyroid cancer in other hospitals come here to 
Table 2. Distribution of the outcomes and malignancy rate in the follow-up cases (%)
Diagnostic category of 
   Bethesda system
Follow-up diagnosis
Malignancy
BN PTC MTC FC PD
I (n=116) 75 (64.7) 41 (35.3) 0 (0) 0 (0) 0 (0) 41 (35.3)
II (n=702) 663 (94.5) 36 (5.1) 0 (0) 2 (0.3) 1 (0.1) 39 (5.6)
III (n=126) 39 (30.9) 84 (66.7) 1 (0.8) 2 (1.6) 0 (0) 87 (69.0)
IV (n=4) 2 (50.0) 2 (50.0) 0 (0) 0 (0) 0 (0) 2 (50.0)
V (n=314) 4 (1.3) 306 (97.4) 3 (1.0) 0 (0) 1 (0.3) 310 (98.7)
VI (n=285) 3 (1.1) 282 (98.9) 0 (0) 0 (0) 0 (0) 282 (98.9)
BN, benign; PTC, papillary carcinoma; MTC, medullary carcinoma; FC, follicular carcinoma; PD, poorly differentiated carcinoma.
Table 3. Distribution of the malignancy rate in follow-up cases by each cytopathologist (%)
Diagnostic category of 
   Bethesda system
Cytopathologists
A (M/T) B (M/T) C (M/T) D (M/T)
I 41.2 (7/17) 48.4 (15/31) 28.0 (7/25) 27.9 (12/43)
II 4.7 (6/128) 4.0 (6/151) 7.4 (9/122) 6.0 (18/301)
III 63.6 (21/33) 73.3 (11/15) 70.0 (21/30) 70.8 (34/48)
IV 33.3 (1/3) 0 (0/0) 0 (0/0) 100.0 (1/1)
V 100.0 (51/51) 95.4 (62/65) 100.0 (68/68) 99.2 (129/130)
VI 98.8 (80/81) 100.0 (43/43) 98.7 (78/79) 98.8 (81/82)
Total 53.0 (166/313) 44.9 (137/305) 56.5 (183/324) 45.5 (275/605)
M, case number of malignancy; T, total case number.
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have their FNA diagnoses confirmed and if possible undergo 
surgery. Baloch et al.10 also reported a high percentage of FNA 
diagnoses in BSRTC categories V and VI (19.1% and 21.3%, 
respectively) in a referral hospital, which is similar to our results. 
Similarly, Lee et al.13 found that 13.0% of FNA diagnoses in a 
referral hospital were classified as category VI.
We also found differences in the malignancy rates of some 
BSRTC categories in our hospital and those reported in previ-
ous studies. For example, the malignancy rates in categories I, 
III, IV, and V in our study (35.3%, 69.0%, 50.0%, and 98.7%, 
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Fig. 1. Receiver operating characteristic curve showing the cut-off value of the diagnostic category of the Bethesda system for the diagnosis 
of histologically-confirmed malignant thyroid by cytopathologists A, B, C, and D. The cut-off values have the following values derived from the 
area under the curve: (A) cytopathologist A: cut-off value>1, 0.513; cut-off value>2, 0.910; cut-off value>3, 0.887; cut-off value>4, 0.891; 
cut-off value>5, 0.738; (B) cytopathologist B: cut-off value>1, 0.507; cut-off value>2, 0.900; cut-off value>3, 0.871; cut-off value>4, 0.871; 
cut-off value>5, 0.654; (C) cytopathologist C: cut-off value>1, 0.544; cut-off value>2, 0.914; cut-off value>3, 0.888; cut-off value>4, 0.888; 
cut-off value>5, 0.706; (D) cytopathologist D: cut-off value>1, 0.528; cut-off value>2, 0.921; cut-off value>3, 0.881; cut-off value>4, 0.879; 
cut-off value>5, 0.646.
Table 4. Sensitivity, specificity, false negative rate, false positive 
rate, positive predictive value, and negative predictive value of the 
malignancy rate by each cytopathologist (%)
Cytopathologists
A B C D
Sensitivity 79.5 76.6 79.8 76.7
Specificity 98.0 98.2 99.3 99.4
False negative rate 20.5 23.4 20.2 23.3
False positive rate 2.0 1.8 0.7 0.6
Positive predictive value 97.8 97.2 99.3 99.1
Negative predictive value 80.9 83.8 79.1 83.7
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respectively) were higher than those reported in the original 
BSRTC guidelines (1-4%, 5-15%, 15-30%, and 60-75%, re-
spectively).1 In addition, the malignancy rates in these catego-
ries in our study were higher than those in the other studies 
that we examined (mean, 24.2%, 33.9%, 37.2%, and 72.6%, 
respectively) (Table 6).2-13 There are two possible reasons for 
these differences. First, although the BSRTC guidelines recom-
mend that patients with categories I or III diagnoses have a re-
peat FNA, in Korea, patients who have thyroid nodules that are 
strongly suspicious for malignancy in a clinical aspect undergo 
surgery without a repeat FNA, but a frozen section examination 
may be performed. Second, Korean patients tend to be more 
concerned about false positive results than false negative results, 
which may pressure cytopathologists to underdiagnose FNA 
cases to avoid making false positive diagnoses. Lee et al.13 also 
reported high malignancy rates for categories III and V (79.0% 
and 97.6%, respectively), which was similar to our result. 
However, their explanation was different from ours; they sus-
pected that their cytopathologists did not properly apply the 
BSRTC classification criteria, which were still relatively new at 
the time of their study. If our explanation that Korean cytopa-
thologists have a tendency to underdiagnose FNA cases is con-
siderable, then clinicians may need to rely on intraoperative di-
agnoses in those cases. As a result, we need to refine and adapt 
to the BSRTC classification criteria or the malignancy rates of 
the BSRTC diagnostic categories may need to be modified. In 
addition, we recommend providing clinicians with current in-
stitutional data about malignancy rates in these categories to 
help them improve their management of thyroid nodule cases.
In this study, we did not find any significant differences in the 
malignancy rates for categories II, V, and VI among four cytopa-
thologists, but found considerable difference in the malignancy 
rates for categories I and III among the cytopathologists. How-
ever, the large number of patients in these categories who did 
not undergo surgery may have biased these results. Several previ-
ous studies have noted that malignancy rates in the BSRTC cat-
egories can differ among cytopathologists both intra- and inter-
institutionally. For example, Layfield et al.14 reported that there 
is wide variation in the malignancy rate for category III diagno-
ses between different institutions and among cytopathologists 
within same institution, depending on whether they had re-
ceived cytopathology fellowship training. Similarly, Wu et al.12 
found that differences in thyroid cytopathology diagnoses may 
arise due to differences in the amount of experience or training 
that cytopathologists have. Furthermore, Cibas and Ali,1 who 
wrote the original BSRTC paper, later admitted that “category 
III may never have good interobserver reproducibility, even after 
pathologists familiarize themselves with the criteria in the at-
las,”15 but they argued that this category was still useful because 
it provides clinically important distinctions for some cases. Since 
category III diagnoses may differ significantly among cytopa-
thologists, we recommend that institutions prepare annual re-
ports about the malignancy rates of diagnoses in categories III-
VI by individual cytopathologists, so clinicians can improve 
their case management of patients with thyroid nodules. We 
also recommend that clinicians consider refining category III in 
Table 5. Comparison of the distribution of the diagnostic categories of the present report with that of other reports (%)
Diagnostic category of 
   Bethesda system
Present 
study
Mondal
et al.3
Jo
et al.4
Yassa
et al.5
Yang
et al.6
Nayar and 
Ivanovic7
Theoharis 
et al.8
Mufti and 
Molah9
Baloch
et al.10
Stamataki 
et al.11
Wu
et al.12
Lee
et al.13
I 13.3 1.2 18.6 7.0 10.4 5.0 11.1 11.6 17.5 4.0 20.1 10.0
II 40.6 87.5 59.0 66.0 64.6 64.0 73.8 77.6 15.8 74.6 39.0 67.7
III 9.1 1.0 3.4 4.0 3.2 18.0 3.0 0.8 9.8 6.7 27.2 3.1
IV 0.4 4.2 9.7 9.0 11.6 6.0 5.5 4.0 16.5 - 8.4 0.6
V 19.3 1.4 2.3 9.0 2.6 2.0 1.4 2.4 19.1 2.8 2.6 5.1
VI 17.3 4.7 7.0 5.0 7.6 5.0 5.2 3.6 21.3 11.9 2.7 13.0
Table 6. Comparison of the distribution of the malignancy rate of the present report with that of other reports (%)
Diagnostic category of 
   Bethesda system
Present 
study
Mondal
et al.3
Jo
et al.4
Yassa
et al.5
Yang
et al.6
Nayar and
Ivanovic7
Theoharis 
et al.8
Mufti and 
Molah9
Baloch 
et al.10
Stamataki 
et al.11
Wu
et al.12
Lee
et al.13
I 35.3 0 8.9 10.0 10.7 9.0 - 20.0 64.0 30.0 12.0 77.8
II 5.6 4.5 11.0 0.3 0.7 2.0 9.8 3.1 11.0 6.0 8.0 0
III 69.0 20.0 17.0 24.0 19.2 6.0 48.0 50.0 50.0 33.0 27.0 79.0
IV 50.0 30.6 25.4 28.0 32.2 14.0 34.0 20.0 63.0 67.0 33.0 61.5
V 98.7 75.0 70.0 60.0 64.8 53.0 87.0 80.0 71.0 - 68.0 97.6
VI 98.9 97.8 98.1 97.0 98.4 97.0 100.0 100.0 100.0 100.0 100.0 100.0
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order to better characterize the threshold for differentiating ma-
lignant cases from benign ones.
Our comparison of malignancy rate was difficult because cat-
egory I, II, and III usually does not require surgery, and distri-
bution of category IV is too small to compare. Other reports 
also commented on the difficulty in comparing malignancy 
rates arising from the same cause.16-18
Our comparisons of the malignancy rates of individual cytopa-
thologists may be limited in two ways. First, there are some 
methodological differences between our study and previous stud-
ies that have compared the FNA diagnoses of individual cytopa-
thologists. Specifically, other studies made comparisons among 
cytopathologists who had all diagnosed the same slides.19-24 
However, this method was not applicable to our study, because 
we performed a retrospective data analysis. In addition, such 
quality control methods are often not practical on a daily basis in 
hospitals. Second, there were no statistically significant differenc-
es in the cut-off value of malignant diagnosis by each cytopa-
thologist. We found that all cytopathologists used category III as 
the cut-off category for differentiating malignant and benign 
cases (p<.0001). Therefore, we suggested that there was no dif-
ference in the malignancy rates of the diagnoses made by indi-
vidual cytopathologists. However, an improvement in cut-off 
value is needed because category III is not appropriate for deter-
mining malignancy.
The sensitivity, specificity, false negative rate, false positive 
rate, positive predictive value, or negative predictive value of 
the malignancy rates of individual cytopathologists were not 
significantly different among cytopathologists. There is some 
limitation due to the large number of cases that were not treat-
ed with surgery.
Conclusion
In conclusion, the distribution of diagnostic categories in this 
institute is shifted towards category V and VI, and the malig-
nancy rates of category I, III, and V were higher than those in 
other reports. Thus, our findings regarding the distribution of 
FNA diagnoses in the BSRTC diagnostic categories and their 
malignancy rates in our hospital suggest the need for future im-
provements in the BSRTC. Specifically, the determination of 
the malignancy rate needs to be modified to reduce additional 
diagnostic procedures, such as intraoperative diagnosis. In addi-
tion, we propose that institutions prepare, communicate, and 
use annual reports of malignancy rates of their cytopathologists’ 
diagnoses to help clinicians practice better case management of 
patients with thyroid nodules.
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